SVB Wealth LLC Decreases Stake in Merck & Co., Inc. $MRK

SVB Wealth LLC decreased its stake in Merck & Co., Inc. (NYSE:MRK) by 20.0% in the 4th quarter, Holdings Channel reports. The firm owned 50,478 shares of the company’s stock after selling 12,631 shares during the quarter. SVB Wealth LLC’s holdings in Merck & Co., Inc. were worth $5,313,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. United Financial Planning Group LLC acquired a new stake in Merck & Co., Inc. in the third quarter valued at $31,000. Wealth Watch Advisors INC acquired a new stake in Merck & Co., Inc. in the 3rd quarter valued at about $34,000. Dunhill Financial LLC increased its holdings in Merck & Co., Inc. by 83.0% during the 3rd quarter. Dunhill Financial LLC now owns 419 shares of the company’s stock valued at $35,000 after acquiring an additional 190 shares in the last quarter. Silicon Valley Capital Partners raised its position in Merck & Co., Inc. by 160.5% during the third quarter. Silicon Valley Capital Partners now owns 422 shares of the company’s stock worth $35,000 after acquiring an additional 260 shares during the last quarter. Finally, J.Safra Asset Management Corp lifted its holdings in shares of Merck & Co., Inc. by 53.6% in the third quarter. J.Safra Asset Management Corp now owns 450 shares of the company’s stock valued at $38,000 after purchasing an additional 157 shares in the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck published a landmark Science paper on a new large-scale biocatalytic synthesis method for its investigational oral PCSK9 inhibitor, enlicitide decanoate. The work supports manufacturing scalability for a potential future cardiovascular drug and underscores progress in Merck’s pipeline. Article Title
• Positive Sentiment: Merck also became the sole testing provider for Genetix Biotherapeutics’ FDA-approved gene therapies under a five-year agreement, strengthening its BioReliance services business and adding a recurring commercialization-related revenue stream. Article Title
• Neutral Sentiment: Analyst commentary highlighted Merck as a well-prepared dividend stock despite its upcoming patent cliff, suggesting the market is still weighing long-term earnings durability rather than reacting to a single catalyst. Article Title
• Negative Sentiment: Merck is heading toward a July 27 trial over Gardasil safety claims after the vaccine reached an $8.9 billion sales peak. The litigation risk could weigh on sentiment around one of Merck’s key growth franchises, even though the company continues to defend the product’s safety record. Article Title

Merck & Co., Inc. Trading Down 0.1%

Shares of Merck & Co., Inc. stock opened at $111.26 on Monday. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $125.14. The business’s fifty day moving average is $117.07 and its two-hundred day moving average is $108.31. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm has a market cap of $274.78 billion, a PE ratio of 31.34, a P/E/G ratio of 2.51 and a beta of 0.18.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter in the previous year, the business earned $2.22 earnings per share. The business’s revenue for the quarter was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts anticipate that Merck & Co., Inc. will post 5.16 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on MRK shares. JPMorgan Chase & Co. lifted their price objective on Merck & Co., Inc. from $125.00 to $135.00 and gave the stock an “overweight” rating in a research report on Monday, April 6th. UBS Group boosted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Citigroup began coverage on Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 price objective on the stock. Zacks Research upgraded Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. Finally, TD Cowen upped their target price on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the company a “hold” rating in a report on Tuesday, January 20th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $128.18.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.